Cognition and NeuroImaging in neuroDegenerative Disorders (CogNID)

Study Overview
=================
Brief Summary
-----------------
This prospective study aims: to compare cognitive performance in different clinical groups of participants with mild cognitive impairment (MCI) or mild dementia [Alzheimer's Disease (AD), Vascular Cognitive Impairment (VCI) and Fronto-temporal Dementia (FTD)] to determine whether scores reveal differential profiles between the groups, to demonstrate differences in imaging markers between different dementia syndromes and healthy volunteers using ultra high-field MRI at 7T.

Detailed Description
-----------------
The imaging arm of the study include: to demonstrate differences in brain iron levels between different dementia syndromes and healthy volunteers using ultra high-field MRI, quantitative susceptibility mapping (QSM) at 7T. to demonstrate variations in the resting oxygen usage as an important biomarker to discriminate between different dementia syndromes. to demonstrate cerebral blood flow changes in the brain, particularly in the hippocampus region, and its correlation with different dementia syndromes using Arterial Spin Labelling MRI technique. to demonstrate increased blood brain barrier leakage in the brain, particularly in the hippocampus region, and its correlation with Alzheimer's Disease (AD) and Vascular Cognitive Impairment (VCI) using a new dynamic contrast-enhanced MRI (DCE-MRI) technique.

Official Title
-----------------
Cognition and NeuroImaging in neuroDegenerative Disorders (CogNID)

Conditions
-----------------
Dementia (Diagnosis)

Intervention / Treatment
-----------------
* Diagnostic Test: Cognitive assessments


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ability to give informed consent. Either pathological, genetic or imaging biomarker evidence to suggest Fronto-temporal Lobar Degeneration, Alzheimer's Disease or Vascular Cognitive Impairment, or defined clinical diagnoses. Exclusion Criteria: Lack of mental capacity to consent to study involvement. Not speaking English before age 5 years. Learning disability. MRI contraindications

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cognitive assessments<br>Neurocognitive assessments, Birmingham Cognitive Screen | |
| MRI at 3T<br>Brain Imaging: MRI at 3T | Diagnostic Test: Cognitive assessments<br>* Cognitive assessment and MRI at 3T and/or 7T<br>* Other names: MRI at 7T;|
| MRI at 7T<br>Brain imaging: Ultrahigh Field MRI at 7T | Diagnostic Test: Cognitive assessments<br>* Cognitive assessment and MRI at 3T and/or 7T<br>* Other names: MRI at 7T;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neurocognitive scales on Birmingham Cognitive Screen (BCoS) Scores | cognitive sub scores in relation to clinical phenotype | Through study completion (an average of one year) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Structural imaging changes on MRI at 3T | Structural volume loss | Through study completion (an average of one year) | 
| Susceptibility weighted mapping at 7T | Quantitative Susceptibility Mapping | Through study completion (an average of one year) |